Combo inhalers get PBAC approval for mild asthma

PBS funding now likely for Symbicort as a first-line therapy

The PBAC has declared budesonide-formoterol combination inhalers should be funded as a first-line treatment for mild asthma for adults and adolescents.


It is a reversal from the expert committee’s announcement in August last year that budesonide-formoterol inhalers had “uncertain” clinical benefits for patients with mild asthma and should not be subsidised by the taxpayer.

AstraZeneca, which filed the application for its combination inhaler Symbicort, was